Get the Stockscreener App
38.29
0.21%
0.0157
Revolution Medicines Inc stock is traded at $38.29, with a volume of 133.60K.
It is up +0.21% in the last 24 hours and down -4.22% over the past month.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
See More
Previous Close:
$38.27
Open:
$38.7
24h Volume:
133.60K
Relative Volume:
0.06
Market Cap:
$7.15B
Revenue:
$29.52M
Net Income/Loss:
$-567.06M
P/E Ratio:
-10.46
EPS:
-3.66
Net Cash Flow:
$-551.11M
1W Performance:
-0.13%
1M Performance:
-4.22%
6M Performance:
-6.78%
1Y Performance:
-18.00%
1-Day Range:
$37.86
$38.78
1-Week Range:
$37.86
$39.62
52-Week Range:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
415-766-3638
Address
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
38.37 | 7.04B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.99 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.85 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.69 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.77 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.08 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Initiated | Goldman | Buy |
| Jul-16-24 | Reiterated | Needham | Buy |
| Jul-12-24 | Initiated | Barclays | Overweight |
| Jul-08-24 | Initiated | Jefferies | Buy |
| Apr-12-24 | Reiterated | Needham | Buy |
| Apr-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - Seeking Alpha
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - The Manila Times
FDA grants breakthrough therapy designation to Revolution Medicines’ lung cancer drug - Investing.com Canada
How will RVMD's EPS trend in Q1 2025? - AInvest
What analysts say about Revolution Medicines Inc. stockFree Bull & Bear Market Updates - jammulinksnews.com
Revolution Medicines Inc. Equity Warrant Stock Analysis and ForecastOutperformance with explosive growth - jammulinksnews.com
What drives Revolution Medicines Inc. stock priceConsistently high returns - jammulinksnews.com
What drives Revolution Medicines Inc. Equity Warrant stock pricePhenomenal trading returns - jammulinksnews.com
Is Revolution Medicines Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Revolution Medicines Inc. Stock Analysis and ForecastRapidly growing investment returns - jammulinksnews.com
What analysts say about Revolution Medicines Inc. Equity Warrant stockExceptional risk-adjusted gains - Autocar Professional
Is Revolution Medicines Inc. Equity Warrant a good long term investmentSky-high profits - Autocar Professional
(RVMD) On The My Stocks Page - news.stocktradersdaily.com
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN
What makes Revolution Medicines Inc. Equity Warrant stock price move sharplyInvestor Friendly Risk Reward - beatles.ru
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
Revolution Medicines’ Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations - MSN
Revolution Meds partners with AI specialist Iambic - The Pharma Letter
Revolution Medicines partners with Iambic for AI-driven drug discovery By Investing.com - Investing.com South Africa
Revolution Medicines, Inc. and Iambic Therapeutics Announce Technology and Research Collaboration Using Iambic's Ai Discovery Tools to Pursue New Drug Candidates - MarketScreener
Revolution Medicines, Iambic Therapeutics Form AI-Powered Drug Discovery Partnership - MarketScreener
Revolution Medicines partners with Iambic for AI-driven drug discovery - Investing.com
Revolution Medicines And Iambic Therapeutics Partner To Develop Novel Drug Candidates Using AI Models In Multi-Year Collaboration; Iambic To Receive Up To $25M Through A Combination Of Upfront And Expected Near-Term Performance-Based Milesto - 富途牛牛
Revolution Medicines and Iambic Therapeutics Announce Collaboration to Explore Novel Drug Candidates Using Advanced AI Models - Quiver Quantitative
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates - The Manila Times
Revolution Medicines and Iambic Announce Technology and - GlobeNewswire
Revolution Medicines Taps Iambic's AI Platform in $25M Deal to Accelerate Cancer Drug Discovery - Stock Titan
Revolution Medicines Inc Stock (RVMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.85%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):